Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema

doi:10.1002/cpt.787

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Remy B. Verheijen, Huixin Yu, Jan H M Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

Original language	English
Pages (from-to)	765-776
Number of pages	12
Journal	Clinical Pharmacology & Therapeutics
Volume	102
Issue number	5
DOIs	https://doi.org/10.1002/cpt.787
Publication status	Published - 12 Jul 2017

Access to Document

10.1002/cpt.787

oncologyFinal published version, 325 KB

Cite this

@article{573efd1c65134f1998137889ed08bbbb,

title = "Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology",

abstract = "Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.",

author = "Verheijen, {Remy B.} and Huixin Yu and Schellens, {Jan H M} and Beijnen, {Jos H} and Neeltje Steeghs and Huitema, {Alwin D R}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics",

year = "2017",

month = jul,

day = "12",

doi = "10.1002/cpt.787",

language = "English",

volume = "102",

pages = "765--776",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

AU - Verheijen, Remy B.

AU - Yu, Huixin

AU - Schellens, Jan H M

AU - Beijnen, Jos H

AU - Steeghs, Neeltje

AU - Huitema, Alwin D R

PY - 2017/7/12

Y1 - 2017/7/12

N2 - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

AB - Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

U2 - 10.1002/cpt.787

DO - 10.1002/cpt.787

M3 - Article

C2 - 28699160

SN - 0009-9236

VL - 102

SP - 765

EP - 776

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 5

ER -

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Abstract

Access to Document

Fingerprint

Cite this